In accordance with health authority requirements and expectations, all third parties with whom Novartis does business, and who provide goods or services that fall within the scope of GxP, including Good Manufacturing Practice (GMP) or Good Distribution Practice (GDP), undergo a formal and rigorous assessment, qualification and monitoring process. The way we oversee quality processes are in place is by requiring all our suppliers to have GMP certifications in place and follow GMP rules. Furthermore, we require our Tier 1 suppliers to ensure that their suppliers (Tier 2) are certified and compliant.
Beyond Tier 1 suppliers (Tier 2+), we follow GMP regulations on outsourced activities which allow for the certification of subcontracted activities (covering all supplier tiers) to be delegated, providing it is contractually defined which party has the GMP responsibilities for each activity, thus ensuring this remains within the requirements of the Marketing Authorization for the product concerned. Following this guidance, we ask from our suppliers to contractually define responsibilities for each activity, thus ensuring Tier 2+ supplier certification.
Our oversight is further enabled by our audits. This includes initial and periodic audits of facilities and quality management processes, with normally more than 1 000 audits of third-party GxP, both direct (Tier 1) and indirect (Tier 2+), performed each year.
Clear definitions, specific expectations, requirements, obligations and responsibilities are described in the Novartis Third Party Code (PDF 0.4 MB) and quality agreements are specific to the type of product or service provided.